Vericel- Potential of MACI
by eneels01 | January 3, 2017 2:47 pm
Can management fully execute on capturing 20k MACI procedures (for knee cartilage repair)? Microfracture procedure costs much less, but MACI has proven superior in a clinical trial. The company’s CEO sees an opportunity to grow from 1100 (former carticel) procedures to as much as 20k/ yr (recent FDA[1] approved MACI procedures). Competition is not seen for at least 3 years. In terms of stock price, I see a potential for $8 by EOY 2017 as Q4 should be EPS positive if the company can execute. Any thoughts?
Endnotes:
- FDA: https://www.stockgumshoe.com/tag/fda/
Source URL: https://www.stockgumshoe.com/2017/01/microblog-vericel-potential-of-maci/
I own it and I agree that it should perform quite well over the next year. Becoming a profitable company is within reach and should be trans-formative for the company. I don’t know if I will hold for a year or not though.
I think the catalysts are coming towards the end of the year and especially on Q4 report in Feb 2018. That one could be big. Orthopedic surgeons have been waiting on MACI in the US for awhile now.
I have alot of shares of this stock and believe by end of summer 2017/beginning of 2018 we will hit $6. current price 2.75. my average is 3